-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Enovis (NYSE:ENOV) & Coloplast A/S (OTCMKTS:CLPBY) Head to Head Contrast
Enovis (NYSE:ENOV) & Coloplast A/S (OTCMKTS:CLPBY) Head to Head Contrast
Enovis (NYSE:ENOV – Get Rating) and Coloplast A/S (OTCMKTS:CLPBY – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Earnings and Valuation
This table compares Enovis and Coloplast A/S's gross revenue, earnings per share and valuation.
Get Enovis alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Enovis | $3.85 billion | 0.88 | $71.66 million | $0.48 | 131.19 |
Coloplast A/S | $2.76 billion | 9.37 | $585.21 million | $0.28 | 42.79 |
Coloplast A/S has lower revenue, but higher earnings than Enovis. Coloplast A/S is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Enovis and Coloplast A/S's net margins, return on equity and return on assets.Net Margins | Return on Equity | Return on Assets | |
Enovis | 0.94% | 4.46% | 2.78% |
Coloplast A/S | 21.62% | 69.30% | 33.77% |
Insider & Institutional Ownership
96.7% of Enovis shares are held by institutional investors. Comparatively, 0.1% of Coloplast A/S shares are held by institutional investors. 8.3% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk & Volatility
Enovis has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Coloplast A/S has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Enovis and Coloplast A/S, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Enovis | 0 | 2 | 7 | 0 | 2.78 |
Coloplast A/S | 1 | 2 | 2 | 0 | 2.20 |
Enovis presently has a consensus target price of $63.50, suggesting a potential upside of 0.84%. Given Enovis' stronger consensus rating and higher probable upside, research analysts clearly believe Enovis is more favorable than Coloplast A/S.
Summary
Enovis beats Coloplast A/S on 9 of the 14 factors compared between the two stocks.
About Enovis
(Get Rating)
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
About Coloplast A/S
(Get Rating)
Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products. The Wound & Skin Care segment covers the sale of wound and skin care products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
Enovis (NYSE:ENOV – Get Rating) and Coloplast A/S (OTCMKTS:CLPBY – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Enovis(NYSE:ENOV-GET Rating)和Colopast A/S(OTCMKTS:CLPBY-GET Rating)都是醫療公司,但哪一家業務更好?我們將根據這兩家公司的機構持股、股息、盈利能力、收益、分析師建議、風險和估值等方面的實力進行比較。
Earnings and Valuation
收益和估值
This table compares Enovis and Coloplast A/S's gross revenue, earnings per share and valuation.
此表比較了Enovis和Colopast A/S的毛收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Enovis | $3.85 billion | 0.88 | $71.66 million | $0.48 | 131.19 |
Coloplast A/S | $2.76 billion | 9.37 | $585.21 million | $0.28 | 42.79 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
伊諾維斯 | 38.5億美元 | 0.88 | 7166萬美元 | $0.48 | 131.19 |
葉綠體A/S | 27.6億美元 | 9.37 | 5.8521億美元 | $0.28 | 42.79 |
Coloplast A/S has lower revenue, but higher earnings than Enovis. Coloplast A/S is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.
Colplast A/S的收入低於Enovis,但收益高於Enovis。Colopast A/S的市盈率低於Enovis,表明它目前是兩隻股票中更負擔得起的一隻。
Profitability
盈利能力
Net Margins | Return on Equity | Return on Assets | |
Enovis | 0.94% | 4.46% | 2.78% |
Coloplast A/S | 21.62% | 69.30% | 33.77% |
淨利潤率 | 股本回報率 | 資產回報率 | |
伊諾維斯 | 0.94% | 4.46% | 2.78% |
葉綠體A/S | 21.62% | 69.30% | 33.77% |
Insider & Institutional Ownership
內部人與機構所有權
96.7% of Enovis shares are held by institutional investors. Comparatively, 0.1% of Coloplast A/S shares are held by institutional investors. 8.3% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Enovis 96.7%的股份由機構投資者持有。相比之下,科萊普斯特A/S公司0.1%的股份由機構投資者持有。Enovis 8.3%的股份由公司內部人士持有。強大的機構持股表明,對衝基金、捐贈基金和大型基金管理公司相信,一家公司有望實現長期增長。
Risk & Volatility
風險與波動性
Enovis has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Coloplast A/S has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
Enovis的Beta值為2.04,表明其股價的波動性比標準普爾500指數高104%。相比之下,Colopast A/S的貝塔係數為0.28,表明其股價的波動性比標準普爾500指數低72%。
Analyst Recommendations
分析師建議
This is a summary of current recommendations and price targets for Enovis and Coloplast A/S, as provided by MarketBeat.com.
這是由MarketBeat.com提供的對Enovis和Colopast A/S的當前建議和目標價的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Enovis | 0 | 2 | 7 | 0 | 2.78 |
Coloplast A/S | 1 | 2 | 2 | 0 | 2.20 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
伊諾維斯 | 0 | 2 | 7 | 0 | 2.78 |
葉綠體A/S | 1 | 2 | 2 | 0 | 2.20 |
Enovis presently has a consensus target price of $63.50, suggesting a potential upside of 0.84%. Given Enovis' stronger consensus rating and higher probable upside, research analysts clearly believe Enovis is more favorable than Coloplast A/S.
Enovis目前的共識目標價為63.50美元,暗示潛在上行0.84%。鑑於Enovis的更高共識評級和更高的可能上行空間,研究分析師顯然認為Enovis比Colplast A/S更有利。
Summary
摘要
Enovis beats Coloplast A/S on 9 of the 14 factors compared between the two stocks.
在兩隻股票之間進行比較的14個因素中,Enovis有9個勝過Colplast A/S。
About Enovis
關於Enovis
(Get Rating)
(獲取評級)
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Enovis公司是一家全球性的醫療技術公司。該公司開發、製造和分銷醫療器械產品,供整形外科專家、外科醫生、初級保健醫生、疼痛管理專家、物理治療師、足科醫生、脊椎按摩師、運動訓練師和其他醫療保健專業人員使用,以治療因退行性疾病、畸形、創傷事件和運動相關傷害而導致的肌肉骨骼疾病患者。它提供堅硬和柔軟的矯形支撐、冷熱治療產品、骨生長刺激器、血管治療系統和加壓服裝、治療鞋和襯墊、用於疼痛管理的電刺激器和物理治療產品;以及一套用於髖關節、膝部、肩部、肘部、足部、腳踝和手指的重建關節產品。Enovis Corporation通過醫療保健專業人員、消費者零售店和藥店等獨立分銷商銷售其產品,並直接以DJO品牌銷售。該公司的前身是科爾法克斯公司。Enovis公司總部設在特拉華州威爾明頓。
About Coloplast A/S
關於Colplast A/S
(Get Rating)
(獲取評級)
Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products. The Wound & Skin Care segment covers the sale of wound and skin care products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.
Colplast A/S公司開發、製造和營銷醫療產品。它通過以下部分開展工作:慢性護理、介入泌尿外科和創傷與皮膚護理。慢性護理部門包括造口護理產品和失禁護理產品的銷售。介入泌尿外科部門涵蓋了泌尿外科產品的銷售,包括一次性產品。傷口和皮膚護理部門包括傷口和皮膚護理產品的銷售。該公司由Aage Louis-Hansen和Johanne Louise-Hansen於1954年創立,總部設在丹麥的Humlebaek。
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Enovis Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Enovis和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧